Isuzinaxib

DB19109InvestigationalSmall molecule

Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).

Mechanism: Pharmacologically active on NADPH oxidase and NADPH oxidase 5
Curator reviewed
Formula / weight: C₁₇H₁₇N₃O · 279.343 g/mol (avg)
Also known as: 1-(pyridin-2-yl)-3-phenyl-4-propyl-1h-pyrazol-5-ol · 1h-pyrazol-5-ol, 3-phenyl-4-propyl-1-(2-pyridinyl)- · 3-phenyl-4-propyl-1-(2-pyridinyl)-1h-pyrazol-5-ol · 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol · Apx-115 free base

Resolves to

Compound

UNIIYP664UDC7TCAS1270084-92-8ChEMBLCHEMBL4650894

Structure

InChIKeyLQKQLKMTJOMCMJ-UHFFFAOYSA-NSMILESCCCC1=C(O)N(N=C1C1=CC=CC=C1)C1=CC=CC=N1

Targets

Q96PH1NOX5

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Isuzinaxib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account